مورد إلكتروني
Management of Advanced Small Intestinal Neuroendocrine Tumors
| العنوان: | Management of Advanced Small Intestinal Neuroendocrine Tumors |
|---|---|
| بيانات النشر: | Medicin 2011 |
| تفاصيل مُضافة: | Öberg, Kjell |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Small intestinal neuroendocrine tumors (carcinoids) are the most common neuroendocrine tumor (NET) within the gastrointestinal tract (15–20%). The incidence and prevalence is steadily increasing during the last decade and the estimated incidence is now about 2.5/100 000/year. The majority of the tumors produce peptides and amines giving rise to clinical symptoms related to the hormone production such as the carcinoid syndrome with flushing, diarrhea, bronchial constriction, and carcinoid heart disease. The majority of patients present with metastatic disease (60%) and therefore a surgical cure is not obtainable. The medical treatment consists of somatostatin analogs, alpha interferons, and targeted treatment with mTOR- and tyrosine kinase-inhibitors. Somatostatin analogs are still the gold standard for treatment of carcinoid tumors with hormone-related clinical symptoms. A possible antitumor effect has been debated, but a recent study (PROMID) has demonstrated an antitumor effect of octreotide LAR, 30 mg, every 4 weeks versus placebo. Tyrosine kinase inhibitors have been applied mostly for antiangiogenic purposes with objective responses in 10–20% of the patients and PFS of 10–15 months. The mTOR-inhibitor everolimus have demonstrated an antitumor effect in patients with carcinoid tumors in the RADIANT-2 trial. Cytotoxic treatment has demonstrated a limited efficacy in classical low proliferation well-differentiated neuroendocrine gastrointestinal tumors and should not be considered first-line treatment. The future treatment will be based on tumor biology and molecular genetics taking into account the new classification systems. The treatment will be personalized. |
| مصطلحات الفهرس: | Carcinoid tumors, carcinoid syndrome, somatostatin analogs, alpha interferon, tyrosine kinase- and mTOR inhibitors, Medical and Health Sciences, Medicin och hälsovetenskap, Article in journal, info:eu-repo/semantics/article, text |
| URL: | European journal of clinical & medical oncology, 1759-8966, 2011, 3:1, s. 64-70 |
| الإتاحة: | Open access content. Open access content info:eu-repo/semantics/restrictedAccess |
| ملاحظة: | English |
| أرقام أخرى: | UPE oai:DiVA.org:uu-153429 1234282186 |
| المصدر المساهم: | UPPSALA UNIV LIBR From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1234282186 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |